Company intelligence / Profile preview

Thryv Therapeutics Inc.

Montreal/Laval, Quebec, Canadathryvtrx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 1 dosing of second SGK1 inhibitor THRV-1268. Received positive top-line results from Wave I Part 2 proof-of-concept clinical study for LQT-1213 in Long QT Syndrome Type 2 and Type 3 patients, showing clinically meaningful and statistically significant reductions in QTcF interval after two days of dosing. LQT-1213 was generally well-tolerated with no drug-related adverse events reported.

Therapeutic areas: OncologyCardiovascular
Modalities: Small molecules (SGK1 inhibitors)
Industry: Biotech

Drug pipeline

5 assets

THRV-1268

4 more assets in the full pipeline.

Beyond the preview

Go deeper on Thryv Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thryv Therapeutics Inc..